Entera Bio Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Entera Bio's earnings are forecast to decline at 72.9% per annum. Der Gewinn pro Aktie wird voraussichtlich sinken um 43.5% pro Jahr.

Wichtige Informationen

-72.9%

Wachstumsrate der Gewinne

-43.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	05 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Mar 23

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Oct 06

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Jun 19

Entera Bio secures European patent for oral PTH formulations

Jun 17

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Mar 20

Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely

Dec 05

Entera Bio EPS misses by $0.22

Nov 19

Entera Bio completes enrollment in Phase 2 trial of EB613 in Osteoporosis

Nov 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ENTX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	N/A	-28	N/A	N/A	1
12/31/2024	N/A	-10	N/A	N/A	1
3/31/2024	N/A	-9	-8	-8	N/A
12/31/2023	N/A	-9	-7	-7	N/A
9/30/2023	0	-10	-7	-7	N/A
6/30/2023	0	-11	-8	-8	N/A
3/31/2023	0	-11	-9	-9	N/A
12/31/2022	0	-13	-13	-12	N/A
9/30/2022	0	-14	-13	-13	N/A
6/30/2022	0	-14	-12	-12	N/A
3/31/2022	0	-14	-12	-12	N/A
12/31/2021	1	-12	-9	-9	N/A
9/30/2021	1	-12	-8	-8	N/A
6/30/2021	1	-10	-9	-9	N/A
3/31/2021	0	-11	-10	-10	N/A
12/31/2020	0	-11	-11	-11	N/A
9/30/2020	0	-11	-12	-12	N/A
6/30/2020	0	-13	-11	-11	N/A
3/31/2020	0	-11	-10	-10	N/A
12/31/2019	0	-11	-9	-9	N/A
9/30/2019	1	-10	-8	-8	N/A
6/30/2019	1	-12	-9	-9	N/A
3/31/2019	1	-9	-9	-9	N/A
12/31/2018	1	-10	-10	-10	N/A
9/30/2018	N/A	-11	-9	-9	N/A
6/30/2018	N/A	-10	-8	-8	N/A
3/31/2018	N/A	-13	-6	-6	N/A
12/31/2017	N/A	-11	N/A	-5	N/A
9/30/2017	N/A	-8	N/A	-4	N/A
6/30/2017	N/A	-6	N/A	-4	N/A
3/31/2017	N/A	-4	N/A	-4	N/A
12/31/2016	N/A	-1	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ENTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ENTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ENTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von ENTX schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: ENTX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ENTX in 3 Jahren voraussichtlich hoch sein wird

Entera Bio Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 97%, EPS upgraded

No longer forecast to breakeven

Price target decreased by 11% to US$6.00

Consensus revenue estimates increase by 59%

Price target increased to US$9.50

Price target increased to US$7.50

Recent updates

Entera Bio Ltd., Annual General Meeting, Jul 31, 2024

Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New minor risk - Shareholder dilution

Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Third quarter 2023 earnings released: US$0.083 loss per share (vs US$0.11 loss in 3Q 2022)

Entera Bio Ltd. Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program

Entera Bio Ltd. Reports Rapid Pharmacodynamic (Pd) Response and Consistent Pharmacokinetic (Pk) Data for Its First-In-Class Oral Pth(1-34) Mini Tablets At the Asbmr 2023 Annual Meeting

New minor risk - Share price stability

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Entera Bio Ltd., Annual General Meeting, Sep 13, 2023

First half 2023 earnings released: US$0.16 loss per share (vs US$0.24 loss in 1H 2022)

Entera Bio Ltd Adds Haya Taitel to its Board of Directors

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Consensus revenue estimates decrease by 97%, EPS upgraded

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022)

Entera Bio Ltd.'S Oral Delivery of GLP-2 Pre-Clinical Data to Be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

No longer forecast to breakeven

Entera Bio Ltd. Announces U.S. Food and Drug Administration Acceptance of Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Price target decreased by 11% to US$6.00

Entera Bio Receives A Notice from Nasdaq Regarding Minimum Bid Price Requirement

Consensus revenue estimates increase by 59%

Price target increased to US$9.50

Insufficient new directors

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Entera Bio Ltd. Announces Fda Agreement for A Single Phase 3 Clinical Trial to Support an NDA for Eb613 for the Treatment of Osteoporosis

Entera Bio Ltd. Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

Price target increased to US$7.50

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M

Insufficient new directors

Entera Bio Ltd., Annual General Meeting, Sep 07, 2022

Entera Bio Ltd. Announces Executive Changes

Insufficient new directors

Entera Bio Ltd. Announces Departure of Dr. Phillip Schwartz, President of Research & Development to Pursue Outside Opportunities

We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Consensus forecasts updated

Entera Bio Ltd. Announces Appointment of Miranda Toledano as Chief Business Officer and Head of Corporate Strategy

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$6.75

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Entera Bio Ltd. Provides Earnings Guidance for the Year Ending December 31, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Entera Bio Ltd. to Report Fiscal Year 2021 Results on Mar 08, 2022

Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

Entera Bio Announces Successful EB613 End-Of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (Bone Mineral Density) as the Primary Endpoint

Consensus forecasts updated

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.086 loss per share (vs US$0.089 loss in 3Q 2020)

Price target decreased to US$11.00

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.17 loss in 2Q 2020)

Entera Bio Ltd. to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting

Forecast to breakeven in 2024

Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints

Consensus forecasts updated

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Entera Bio Receives Foundational Patent for Oral PTH Using Platform Oral Protein Delivery Technology in European Union